Kenvue, the parent company of Tylenol, has publicly defended the safety of its pain reliever following the Trump administration’s reference to a 2017 social media post. The administration had highlighted the post, which raised questions about Tylenol’s usage during pregnancy. Kenvue emphasized its ongoing commitment to safety and regulatory compliance, asserting that the company’s products remain safe for all intended uses.
The social media post in question, which was shared by a former company employee, suggested that Tylenol may not be suitable for use during pregnancy. This sparked a wave of public concern and prompted the Trump administration to bring the issue to public attention. Kenvue swiftly responded, clarifying that the post did not reflect current scientific understanding or product guidelines.
Despite the controversy, Tylenol products continue to be available at retail locations, including a drugstore chain in Buffalo Grove, Ill., on Tuesday. The company has not announced any changes to its product formulation or safety protocols as a result of the administration’s reference to the post. Industry experts suggest that the incident underscores the importance of clear communication and transparency in addressing public health concerns.